drugset / Trial / NCT00656097

A Randomized Phase II Trial to Compare the Safety and Neutralizing Activity of CL184 in Combination With Rabies Vaccine vs. HRIG or Placebo in Combination With Rabies Vaccine in Healthy Adult Subjects

NCT00656097

Phase 2 Completed 140 enrolled Crucell Holland BV
RandomizedParallel-groupSingle-blindTreatment

Summary

The aim of this study is to evaluate the safety of the monoclonal antibody cocktail CL184 in combination with rabies vaccine compared with human rabies immune globulin (HRIG) or placebo in combination with rabies vaccine in healthy adult subjects.

Timeline

Start
2008-03
Primary completion
2008-07
Completion
2008-07

Drugs

EvaluationDrugModalityDoseRoute
Subject CL184 Monoclonal antibody 20 iu/kg Intramuscular
Comparator human rabies immune globulin Unknown 20 iu/kg Intramuscular

Indications